Renal Cell Carcinoma with Polycythemia
Al- Anbar Medical Journal,
2021, Volume 17, Issue 1, Pages 41-43
Abstract
Renal cell carcinoma (RCC) is the most common renal tumor and participates in about 80-85%of primary renal tumors. It is usually diagnosed incidentally during the evaluation for othermedical problems; or it may be presented with gross hematuria, loin mass or pain. However, itinfrequently presents as a paraneoplastic syndrome (PNS) which includes, hypertension, hypercalcemia, and abnormal liver function. A 75-year-old gentleman presented with an incidentalleft renal mass following the evaluation of the left loin pain with headache and dizziness. Thepatient had a history of hypertension for 10 years on control medical therapy and no history ofsmoking or chronic obstructive airway disease. The complete blood picture was showed a markedelevation in hemoglobin 21.7 g/dl and hematocrit level 65%. Ultrasound was showed left renalmass and a computerized tomography scan was showed the enhancement in the left renal masspicture suggestive of RCC. After phlebotomy of 2 units of blood, the patient underwent radicalnephrectomy, then the histopathology was reported clear cell type RCC Fuhrman nuclear gradingsystem II. At 2 months following surgery, the patient’s hemoglobin level and hematocrit werereturned to normal. The pathogenesis of PNS may be due to an abnormal immune system responseto a cancerous cell. There is a wide range of the PNS concerning RCC including non-specificconstitutional features for example; cachexia, weight loss, and fever, and specific metabolic andbiochemical disorders (i.e. hypercalcemia, non-metastatic hepatic dysfunction, amyloidosis, etc.).PNS is often unrecognized but polycythemia should be considered important biomarkers in RCC,therefore, it can be used as a tumor marker in the diagnosis and follow-up of the patient after surgery.[1] J.-L. Da Silvaet al.Tumor cells are the site of erythro-
poietin synthesis in human renal cancers associated with
polycythemia. 1990.
[2] K. Itoet al.Impact of increased erythropoietin receptor
expression and elevated serum erythropoietin levels on
clinicopathological features and prognosis in renal cell
carcinoma.Exp. Ther. Med., 3(6):937–944, 2012.
[3] C. Lacombeet al.Peritubular cells are the site of ery-
thropoietin synthesis in the murine hypoxic kidney.J.
Clin. Invest., 81(2):620–623, 1988.
[4] B. Ljungberg, T. Rasmuson, and K. Grankvist. Erythro-
poietin in renai celi carcinoma: evaluation of its useful-
ness as a tumor marker.Eur. Urol., 21:160–163, 1992.
[5] K. Uedaet al.Successful treatment of erythropoietin-
producing advanced renal cell carcinoma after targeted
therapy using sunitinib:Case report and review of the
literature.Mol. Clin. Oncol., 1(1):112–116, 2013.
[6] R. L. Siegel and K. D. Miller. Cancer statistics. 70(1):7–
30, 2020.
[7] J. Kopel, P. Sharma, I. Warriach, and S. Swarup. Poly-
cythemia with renal cell carcinoma and normal erythro-
poietin level.Case Rep. Urol., 2019, 2019.
[8] J.-J. Patardet al.Prognostic value of histologic subtypes
in renal cell carcinoma: a multicenter experience.J. Clin.
Oncol., 23(12):2763–2771, 2005.
[9] G. Dinget al.Paraneoplastic symptoms: Cachexia, poly-
cythemia, and hypercalcemia are, respectively, related to
vascular endothelial growth factor (vegf) expression in
renal clear cell carcinoma.Urologic Oncology: Seminars
and Original Investigations, 31(8):1820–1825, 2013.
[10] M. Okuyama, M. Nishihara, H. Hashimoto, S. Kaneko,
and S. Yachiku.A case of erythropoietin-producing re-
nal cell carcinoma with polycythemia.Hinyokika Kiyo.,
48(9):531, 2002.
[11] K. Ito, T. Asano, S. Tominaga, H. Yoshii, H. Sawazaki,
and T. Asano.Erythropoietin production in renal cell
carcinoma and renal cysts in autosomal dominant poly-
cystic kidney disease in a chronic dialysis patient with
polycythemia:A case report.Oncol. Lett., 8(5):2032–
2036, 2014.
- Article View: 15
- PDF Download: 7